EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY 4.0

Stakeholder Perspectives on the Design of First‐In‐Human Trials for Artificial Amnion and Placenta Technology: A Qualitative Study

Angret de Boer iD, André Krom iD, Rania Kalaai, Marieke de Vries, Marije Hogeveen iD, Sylvia A Obermann-Borst iD, Marijn Vermeulen iD, M Beatrijs van der Hout-van der Jagt iD, Juliette S van Haren iD, Peter Andriessen iD, Martine C de Vries iD, Rosa Geurtzen iD und 1 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 2025

DOI: 10.1111/1471-0528.18189 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2025. Verfasst von Angret de Boer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Amnion, Stakeholder Participation, Parents, Placenta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Society for Paediatric Research, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Artificial Amnion and Placenta Technology (AAPT), designed to improve outcomes in extreme prematurity, has shown promise in animal studies, with human trials anticipated soon. This study seeks to inform the responsible design of future trials by utilising insights from parents who experienced an (imminent) extremely premature birth and perinatal healthcare professionals (HCPs).

Design

A qualitative study using individual and focus group interviews.

Setting

This study was part of a Dutch study called Toward Individualised care of the Youngest. Sample Fifteen parents who experienced an (imminent) extremely premature birth and 46 HCPs were interviewed.

Methods

Eight focus‐group and five individual interviews were performed and transcribed. The transcripts were thematically analysed. Main Outcomes and Measures The perspectives of HCPs and experienced parents on what they considered essential for human AAPT trials.

Results

Analyses revealed some critical considerations represented in six themes: (1) optimise the animal model, (2) determine the goal of human trials, (3) carefully establish the research population, (4) formulate stop criteria, success criteria and outcome measures, (5) determine the role for parents during the AAPT trial, and (6) develop protocols for the trial and address logistical considerations.

Conclusion

This study emphasises the critical role of stakeholder involvement in safeguarding the responsible design of human AAPT trials. Defining the trial objectives including well‐defined stop criteria and follow‐up schemes is a key element for the human AAPT trials. Establishing consensus among stakeholders is essential, as shared recommendations will facilitate alignment of expectations and promote engagement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmnionStakeholder ParticipationParentsPlacentaResearch DesignPremature BirthClinical Trials as TopicHumansFemalePregnancyQualitative ResearchFocus GroupsAdultInfant, NewbornInfant, Extremely PrematureNetherlandsMaleAttitude of Health Personnel

Stichwörter der Autor:innen

ectogenesisethicsextremely premature infantfoetal viabilityneonatologyparentsperinatal careplacentaqualitative researchtechnology

Autor:innen und Institutionen

  • Department of Obstetrics, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Neonatology, Radboudumc Amalia Children's Hospital, Nijmegen, the Netherlands.
  • Department of Medical Ethics and Health law, Leiden University Medical Center, Leiden, the Netherlands.
  • Institute for Computing and Information Sciences (iCIS), Radboud University, Nijmegen, the Netherlands.
  • Care4Neo, Neonatal Patient and Parent Advocacy Organization, Rotterdam, the Netherlands.
  • Department of Neonatal and Pediatric Intensive Care, Division of Neonatology, Sophia Children's Hospital, Rotterdam, the Netherlands.

ORCID-Profile: Angret de Boer, André Krom, Marije Hogeveen, Sylvia A Obermann-Borst, Marijn Vermeulen, M Beatrijs van der Hout-van der Jagt, Juliette S van Haren, Peter Andriessen, Martine C de Vries, Rosa Geurtzen, E J T Verweij

Förderung

  • European Society for Paediatric Research
  • ZonMw

Zitieren

APA

de Boer, A., Krom, A., Kalaai, R., de Vries, M., Hogeveen, M., Obermann-Borst, S. A., Vermeulen, M., van der Hout-van der Jagt, M. B., van Haren, J. S., Andriessen, P., de Vries, M. C., Geurtzen, R., & Verweij, E. J. T. (2025). Stakeholder Perspectives on the Design of First‐In‐Human Trials for Artificial Amnion and Placenta Technology: A Qualitative Study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.18189

Vancouver

de Boer A, Krom A, Kalaai R, de Vries M, Hogeveen M, Obermann-Borst SA, et al. Stakeholder Perspectives on the Design of First‐In‐Human Trials for Artificial Amnion and Placenta Technology: A Qualitative Study. BJOG: An International Journal of Obstetrics & Gynaecology. 2025. doi:10.1111/1471-0528.18189

BibTeX
@article{deBoer2025,
  author = {de Boer, Angret and Krom, André and Kalaai, Rania and de Vries, Marieke and Hogeveen, Marije and Obermann-Borst, Sylvia A and Vermeulen, Marijn and van der Hout-van der Jagt, M Beatrijs and van Haren, Juliette S and Andriessen, Peter and de Vries, Martine C and Geurtzen, Rosa and Verweij, E J T},
  title = {Stakeholder Perspectives on the Design of First‐In‐Human Trials for Artificial Amnion and Placenta Technology: A Qualitative Study},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2025},
  doi = {10.1111/1471-0528.18189}
}
Kostenlos starten →